Express News | Bradley L. Radoff and Michael Torok: Collectively Own About 3% of Outstanding Shares of Atea Pharmaceuticals
Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Maintains Target Price $6.2
Atea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market Challenges
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
Arrayfunction : With the +27% cash from financing last quarter, is this corporate speak for "insiders seek greater fool to dump this sinking ship on?"
Jaguar8 OP Arrayfunction : We shall see how it unfolds